Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
February 02, 2021 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as...
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for Research in Biomedicine and Neurocentro
December 15, 2020 10:11 ET
|
Gain Therapeutics
- Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx)™ technology for the treatment of rare genetic and neurodegenerative diseases - The collaborative agreement...
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for Research in Biomedicine and Neurocentro
December 15, 2020 08:00 ET
|
Gain Therapeutics
- Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx) ™ technology for the treatment of rare genetic and neurodegenerative diseases - The collaborative agreement...
Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration
November 30, 2020 09:40 ET
|
Gain Therapeutics
BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM),...
Gain Therapeutics to Present New Preclinical Data on Brain Penetrant Allosteric Regulators at the 14th Meeting of the European Working Group on Gaucher Disease
October 13, 2020 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites...
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
September 10, 2020 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites...
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
July 21, 2020 08:00 ET
|
Gain Therapeutics
Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare genetic and neurodegenerative diseases, expand pipeline and support business development activities Eric...